The impact of SGLT2 inhibitors on renal outcomes in patients with type 2 diabetes and chronic kidney disease: systematic review and meta-analysis
Abstract
Objective: To analyze and evaluate the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease, and to provide evidence-based basis for clinical rational treatment.
Methods: Relevant literatures on the impact of SGLT2 inhibitors on the renal outcomes of patients with type 2 diabetes mellitus and chronic kidney disease published in domestic and foreign databases were retrieved and collected. The time limit was from the establishment of each database to November 2025. After screening, the quality of the research literature was evaluated using the Cochrane library. Literature management was conducted using NoteExpress 3.2, and data collection and extraction were carried out using Excel 2003. Statistical analysis was performed using RevMan 5.4.1 software. Based on the size of the Q test (P value), it was determined whether there was heterogeneity in the studies, and then the fixed or random effect model was used to calculate the combined effect OR value, and a forest plot was drawn. Then, the publication bias was evaluated by drawing a funnel plot.
Results: A total of 10 studies that met the inclusion criteria were finally included. The meta-analysis results showed that compared with the control group, the eGFR and CrCI levels of patients treated with 5 mg dapagliflozin showed a more significant decline, renal-related adverse events (OR = 0.91, 95% CI: 0.84 to 0.99, P = 0.04), and the occurrence of doubling of serum…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.